Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is a clinical-stage biotech company that is making significant strides in the treatment of inflammatory, fibrotic, and autoimmune disorders through its novel drug candidates, GRI-0621 and GRI-0803. The company recently reported positive top-line data for GRI-0621 in a Phase 2a study for IPF, highlighting the drug's potential to bring the immune system back to homeostasis. GRI Bio also has a large market potential in the treatment of lupus with its drug candidate, GRI-0803, and the company's current valuation presents an attractive investment opportunity for its potential to address serious diseases.

Bears say

GRI Bio is a clinical-stage biotech company focused on developing therapies for dysregulated immune response disorders that has recently reported a net loss and no Q1 or Q2 guidance. Despite the potential for treatments in large markets such as Lupus and IPF, the lack of revenue and significant negative earnings make the stock unappealing. Additionally, while recent data for GRI-0621 has been positive, the company's focus on only one product may pose a risk for investors.

GRI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 1 analysts, GRI has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.